- Home
- About
- Section Advisors
- Meet Our Field Medical Affairs Team
- Speakers Bureau
- Supporting Organizations
- Contact Us
- Resource Library
- Mental Health Disorders
- Agitation
- Anxiety Disorders
- Bipolar Disorder
- Cognition
- Depression
- Eating Disorders
- Personality Disorders
- PTSD/Trauma
- Schizophrenia
- Substance Use Disorders
- Women’s Health
- Topics of Interest
- Care Coordination
- Digital Health
- Diversity, Equity, & Inclusion
- Early Episode Psychosis
- Health Care Policy & Legislation
- Neuroscience
- Payer & Financing Models
- Quality Standards & Performance Measures
- Stigma
- Suicide Awareness
- Wellness
- Collections
- Featured
- Monthly Spotlight
- Psychopharmacology
- Learning Tracks
- Community Insights
- Community Podcast
- Disease Management & Support Tools
- Frameworks In Health & Quality Resources
- Mental Health System Guidebooks
- Patient & Caregiver Resource Center
- PsychU Roleplay
- Psychiatric Scales
- PsychUSim
- Events
Distinguishing Sedation From Efficacy In Antipsychotic Treatment
Distinguishing Sedation From Efficacy In Antipsychotic Treatment
A Virtual Live Event for PsychU members in Florida.
This presentation will highlight the importance of distinguishing sedation from antipsychotic treatment efficacy. Symptomatology of acute agitation, neurobiological mechanisms for sedation, and potential consequences of long-term sedation will be discussed to review pharmacologic considerations when selecting an antipsychotic.
Featuring
-
Jacquelyn Canning, PharmD, BCPP (OPDC)
Clinical & Scientific Liaison
-
Aneta Fornal, PharmD (OPDC)
Clinical & Scientific Director
Speakers are paid consultants for Otsuka Pharmaceutical Development & Commercialization, Inc.
Related Events
-
Virtual Event – Trace Amine-Associated Receptor 1 (TAAR1): A Potential New Target For The Treatment of Schizophrenia
February 14 3:00 pm to 4:00 pm
Register
This event registration is closed.
Stay Connected: